ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET ANALYSIS

Regional Analysis

Regional Dynamics

Regional segmentation of the global acute lymphoblastic leukemia therapeutics market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global acute lymphoblastic leukemia therapeutics market over the forecast period, owing to rising prevalence of the disease and rising number of clinical trials undertaken by organizations in the region to address the unmet medical needs of patients. According to the American Cancer Society, 2016, an estimated 5,970 new ALL diagnoses and 1,440 deaths from ALL were registered in 2017. Also, according to the St. Jude Children's Research Hospital, about 3,000 people aged below 20 years are found to have acute lymphoblastic leukemia each year in the U.S.

Moreover, the St. Jude Children’s Research Hospital, U.S. is focusing on improving outcomes for children with leukemia by undertaking clinical trials to develop novel therapeutics for the condition. For instance, in 2012, the St. Jude Children’s Research Hospital initiated trials for ALLR18 for pediatric relapsed or refractory precursor B-cell acute lymphoblastic leukemia. Moreover, in 2015, Juno Therapeutics, Inc. developed JCAR015 (CD19-targeted CAR T cells), which is currently in the Phase 2 clinical trial, indicated for treating adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).